SAFECVAD is the world's first patented "inside-out" retrograde central venous access device that profoundly improves patient safety, resulting in drastically lower costs of complications. With SAFECVAD™, Interventionist physicians can achieve faster, low-risk procedures. Central venous (CV) access is required for the treatment of many common medical conditions, including cancer, kidney failure, infections and cardiovascular diseases.The procedure is associated with an abnormally high rate of complications, particularly for patients whose conditions, such as morbid obesity, reduce the success rate or aggravate complications resulting from failed access attempts. Of the millions of central venous access procedures performed annually, approximately• 158,000 procedures result in severe or potentially life-threatening complications.• 11,000 Patients Die• 4.4 additional hospital days per patient to treat complications• $17,312 in Excess Charges for these complications